10-Q quarterly report · filed Nov 4, 2026

CVS Health (CVS) Q3 2026 10-Q Quarterly Report

Short answer

CVS Health (CVS) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $108.4B (up 5.4% year over year) with net income of $2.2B.

Q3 2026 key financials · XBRL

Revenue
$108.4B
+5.4% YoY · +2.2% QoQ
Net income
$2.2B
+154.6% YoY · −27.1% QoQ
Operating margin
3.3%
EPS (diluted)
$1.68
+153.5% YoY · −27.3% QoQ

Source: XBRL data from the CVS Health (CVS) Q3 2026 10-Q on SEC EDGAR. USD.

CVS Health Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $108.4B, up 5.4% YoY from $102.9B, driven by Health Services and Health Care Benefits
  • Operating margin 3.3% vs (3.1)% YoY, with operating income $3.6B vs $3.2B loss
  • Best segment Health Services: revenue $54.0B, up 9.5%; adjusted operating margin 3.9% vs 4.2%
  • Worst segment Pharmacy & Consumer Wellness: revenue $35.5B, down 2.0%; adjusted operating margin 4.6% vs 4.1%
  • Cash $11.7B; nine-month operating cash flow $15.3B, up $8.1B, with $5.5B investing outflows and no share repurchases
  • Outlook headwinds: elevated utilization, PBM pricing pressure, regulatory changes, inflation, tariffs and weaker discretionary spending

Risk Factors

  • Newly added separation risk triggered by November 4, 2026 announcement to create CVS Health and CVS Pharmacy
  • Operational risk: management distraction from separation could disrupt ongoing business and adversely affect results
  • Regulatory and tax risk: separation requires SEC Form 10 effectiveness and confirmation of tax-free treatment
  • Execution risk: separation expected first half of 2028, subject to Board approval and independent-company readiness
  • Financial risk: dis-synergy, restructuring and transaction costs could exceed estimates

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other CVS Health quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.